ArticleHuman vaccines & immunotherapeutics2025
Effectiveness of Universal Varicella Vaccination after ten years of implementation in Tuscany (Central Italy).
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Varicella vaccination is currently recommended in several European countries, including Italy. Tuscany Region introduced Universal Varicella Vaccination (UVV) in 2008, and it was later included in the Italian National Immunization Plan 2017-2019. Recently, it has also been made mandatory in Italy for school attendance. The aim of our study was to assess the effectiveness of the UVV program in preventing varicella cases and related hospitalizations in children born between 2008 and 2017, during the pre-pandemic period (2010-2019) in Tuscany (Central Italy). We applied the screening method to assess varicella vaccine effectiveness (VE) for the first and the second vaccine dose in the birth cohorts targeted by the UVV. We considered the vaccination coverage (VC) at 24 months and at 5-6 y of age, and we verified the vaccination status of each notified or hospitalized case to identify breakthrough varicella cases (BV). We assessed a VE of 84.8% (95%CI:83.5-85.9%) for at least one varicella vaccine dose and 95.7% (95% CI: 93.6-97.1%) for the second dose in preventing notifications. VE in preventing hospitalizations was 98.5% (95% CI: 96.7-99.3%) after one dose and 100% after two doses. The median time interval between the first or second vaccine dose and the onset of varicella was 34 months and 28 months, respectively. Our study demonstrated the excellent vaccine effectiveness profile of the vaccines used over a 10-y period in Tuscany, in preventing notified and hospitalized varicella cases in the target cohorts of children, confirming the health benefits of the UVV in Central Italy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.